Skip to content
Colorectal Cancer Clinical Trials

Cincinnati, Ohio

Colorectal cancer clinical trials in Cincinnati, OH

30 colorectal cancer studies are recruiting participants at sites in Cincinnati as of November 16, 2026, according to ClinicalTrials.gov. Colorectal Cancer Clinical Trials can help you understand your options and connect with a study team.

Call (888) 385-9581
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Cincinnati at a glance

  • 30 studies are recruiting at a site in Cincinnati.
  • By phase: Phase 1 (6), Phase 1/2 (6), Phase 2 (3), Phase 2/3 (1), Phase 3 (8), No phase (3), Observational (3). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (20), university, hospital or other (8), government (2).
  • Most recent update to one of these records: November 12, 2026.

Studies recruiting in Cincinnati

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Cincinnati Medical Center ( Site 2005)
    Registry record
    NCT06997497 · updated
  2. Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Bethesda North Hospital · Good Samaritan Hospital - Cincinnati · TriHealth Cancer Institute-Anderson
    Registry record
    NCT07018869 · updated
  3. Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Registry record
    NCT07228832 · updated
  4. FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Oncolytics Biotech
    Study site
    University of Cincinnati Medical Center
    Registry record
    NCT07446322 · updated
  5. Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

    • No phase
    • Ages 45 to 70
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    Bethesda North Hospital · Good Samaritan Hospital - Cincinnati · TriHealth Cancer Institute-Anderson
    Registry record
    NCT05080673 · updated
  6. Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    Bethesda North Hospital · Good Samaritan Hospital - Cincinnati · Oncology Hematology Care Inc-Kenwood
    Registry record
    NCT05174169 · updated
  7. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    • Observational
    • Ages 40 to 75
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Bethesda North Hospital · Good Samaritan Hospital - Cincinnati · Oncology Hematology Care Inc-Kenwood
    Registry record
    NCT05334069 · updated
  8. Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Bethesda North Hospital · Good Samaritan Hospital - Cincinnati · TriHealth Cancer Institute-Anderson
    Registry record
    NCT07283939 · updated
  9. Family Communications After Genetic Testing

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Bethesda North Hospital · Good Samaritan Hospital - Cincinnati · Oncology Hematology Care Inc-Kenwood
    Registry record
    NCT07143487 · updated
  10. A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study site
    University of Cincinnati Cancer Institute
    Registry record
    NCT07284849 · updated
  11. Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Cincinnati Cancer Center-UC Medical Center
    Registry record
    NCT05803382 · updated
  12. A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    Oncology Hematology Care - Eastgate /ID# 271493
    Registry record
    NCT06820463 · updated
  13. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Artios Pharma Ltd
    Study site
    Oncology Hematology Care Primary
    Registry record
    NCT04657068 · updated
  14. A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    Oncology Hematology Care - Blue Ash /ID# 280143
    Registry record
    NCT07525206 · updated
  15. Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Cincinnati Cancer Center-UC Medical Center
    Registry record
    NCT06654037 · updated
  16. Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    Oncology Hematology Care - Eastgate
    Registry record
    NCT07222800 · updated
  17. A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Dispatch Biotherapeutics
    Study site
    University of Cincinnati Cancer Center
    Registry record
    NCT07544589 · updated
  18. Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

    • Phase 2
    • Ages 18 to 130
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT05489211 · updated
  19. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    University of Cincinnati Medical Center
    Registry record
    NCT06445062 · updated
  20. Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

    • Phase 1
    • Ages 12 to 85
    • All sexes
    Sponsor
    Inhibrx Biosciences, Inc
    Study site
    Cincinnati Children's Hospital Medical Center
    Registry record
    NCT03715933 · updated
  21. Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

    • Phase 1/2
    • From 12 months, up to 30 years
    • All sexes
    Sponsor
    Children's Oncology Group
    Study site
    Cincinnati Children's Hospital Medical Center
    Registry record
    NCT04851119 · updated
  22. Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Xencor, Inc.
    Study site
    Xencor Investigative Site
    Registry record
    NCT05433142 · updated
  23. Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Canadian Cancer Trials Group
    Study site
    University of Cincinnati Cancer Center-UC Medical Center
    Registry record
    NCT06205485 · updated
  24. Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study site
    University of Cincinnati Cancer Center
    Registry record
    NCT03947385 · updated
  25. Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    The Christ Hospital
    Registry record
    NCT06040541 · updated
  26. Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Christ Hospital Cancer Center
    Registry record
    NCT05379985 · updated
  27. Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    GlaxoSmithKline
    Study site
    GSK Investigational Site
    Registry record
    NCT05855200 · updated
  28. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    • Observational
    • All ages
    • All sexes
    Sponsor
    Massive Bio, Inc.
    Study site
    Massive Bio SYNERGY-AI site
    Registry record
    NCT03452774 · updated
  29. 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

    • Phase 1/2
    • Ages 15 and older
    • All sexes
    Sponsor
    Lantheus Medical Imaging
    Study site
    Cincinnati Children's Hospital Medical Center
    Registry record
    NCT06298916 · updated
  30. Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    Tempus AI
    Study site
    TriHealth Cancer Institute
    Registry record
    NCT05234177 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Cincinnati, OH on ClinicalTrials.gov.

Ask about studies near Cincinnati

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Ohio

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 385-9581

or send a short form

How should we reach you?

Call